Notably, median sensitivities closely matched that for BRCA2-mutated, cisplatin-hypersensitive CAPAN140, indicating high platinum sensitivity across osteosarcoma lines, irrespective of status and PARPi sensitivity. The gene discussed is BRCA2; the disease is osteosarcoma.